Skip to main content
SpringerLink
Log in

Adenosine as an Adjunct Therapy in ST Elevation Myocardial Infarction Patients: Myth or Truth?

  • REVIEW ARTICLE
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Early reperfusion represents the key strategy in ST elevation myocardial infarction. However, reperfusion may induce myocardial damage due to the reperfusion myocardial injury, compromising the full potential of reperfusion therapy and accounting for unfavourable results in high risk patients. Adenosine seems to attenuate ischemia reperfusion injury, and thus represents a promising therapeutic option for treating such patients. However, previous randomized clinical trials have collectively failed to demonstrate whether adenosine can effectively reduce measures of myocardial injury and improve clinical outcome, despite its good basic evidence. The failure of such trials to show a real beneficial action may be in part related to specific factors other than adenosine’s clinical efficacy. The purpose of this review is to explain the rationale for the use of adenosine as an adjunctive pharmacological cardio-protective agent following reperfusion of the ischemic myocardium, to address the weakness of previous trials and to summarize the current state of knowledge regarding the effect of adenosine administration on reperfusion myocardial injury in patients with myocardial infarction. Although some preclinical and clinical studies point towards the beneficial role of adenosine in the prevention and treatment of no-reflow phenomenon in myocardial infarction, many unanswered questions still remain, including the optimal clinical indication, mode, dosage, duration and timing of application, and the exact mechanisms leading to potential benefits. Clarifying these issues will depend on further properly designed, adequately powered and well conducted clinical trials, which will probably provide us with the definite answers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gibson CM, Schoming A. Coronary and myocardial angiography. Angiographic assessment of both epicardial and myocardial perfusion. Circulation. 2004;109:3096–105.

    PubMed  Google Scholar 

  2. De Maria GL, Patel N, Kassimis G, Banning AP. Spontaneous and procedural plaque embolisation in native coronary arteries: pathophysiology, diagnosis, and prevention. Sci(Cairo). 2013;2013:364247.

    Google Scholar 

  3. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54:281–92.

    PubMed  Google Scholar 

  4. Galiuto L, Lombardo A, Maseri A, et al. Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. Heart. 2003;89:731–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  5. Jaffe R, Charron T, Puley G, et al. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008;117:3152–6.

    PubMed  Google Scholar 

  6. Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;55:2383–9.

    PubMed  Google Scholar 

  7. Rezkalla SH, Kloner RA. Coronary no reflow phenomenon: from the experimental laboratory to the cardiac catherization laboratory. Catheter Cardiovasc Interv. 2008;72:950–7.

    PubMed  Google Scholar 

  8. Klein LW, Kern MJ, Berger P, et al. Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catherization laboratory. Catheter Cardiovasc Interv. 2003;60:194–201.

    PubMed  Google Scholar 

  9. Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. Myocardial ischemia/reperfusion injury, a clinical view on a complex pathophysiological process. Int J Cardiol. 2005;100:179–90.

    CAS  PubMed  Google Scholar 

  10. Van’t Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet. 1997;350:615–9.

    Google Scholar 

  11. Brodie BR, Stuckey TD, Hansen C, et al. Relation between electrocardiographic ST-segment resolution and early and late outcomes after primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2005;95:343–8.

    PubMed  Google Scholar 

  12. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125–30.

    CAS  PubMed  Google Scholar 

  13. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI study group. N Engl J Med. 1985;312:932–6.

    Google Scholar 

  14. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879–88.

    CAS  PubMed  Google Scholar 

  15. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002;105:1909–13.

    PubMed  Google Scholar 

  16. Van’t Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial infarction Study Group. Circulation. 1998;97:2302–6.

    Google Scholar 

  17. Hozumi T, Kanzaki Y, Ueda Y, et al. Coronary flow velocity analysis during short term follow up after coronary reperfusion: use of transthoracic Doppler echocardiography to predict regional wall motion recovery in patients with acute myocardial infarction. Heart. 2003;89:1163–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  18. Kamp O, Lepper W, Vanoverschelde JL, et al. Serial evaluation of perfusion defects in patients with a first acute myocardial infarction referred for primary PTCA using intravenous myocardial contrast echocardiography. Eur Heart J. 2001;22:1485–95.

    CAS  PubMed  Google Scholar 

  19. Uren NG, Crake T, Lefroy DC, de Silva R, Davies GJ, Maseri A. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med. 1994;331:222–7.

    CAS  PubMed  Google Scholar 

  20. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765–72.

    CAS  PubMed  Google Scholar 

  21. Lepper W, Hoffmann R, Kamp O, et al. Assessment of myocardial reperfusionby intravenous myocardial contrast echocardiography and coronary flow reserve after primary percutaneous transluminal coronary angioplasty [correction of angiography] in patients with acute myocardial infarction. Circulation. 2000;101:2368–74.

    CAS  PubMed  Google Scholar 

  22. Cuculi F, Dall’Armellina E, Manlhiot C, et al. Early change in invasive measures of microvascular function can predict myocardial recovery following PCI for ST-elevation myocardial infarction. Eur Heart J. 2014;35:1971–80.

    CAS  PubMed  Google Scholar 

  23. Feldman LJ, Himbert D, Juliard JM, et al. Reperfusion syndrome: relationship of coronary blood flow reserve to left ventricular function and infarct size. J Am Coll Cardiol. 2000;35:1162–9.

    CAS  PubMed  Google Scholar 

  24. Feldman LJ, Coste P, Furber A, et al. Incomplete resolution of ST-segment elevation is a marker of transient microcirculatory dysfunction after stenting for acute myocardial infarction. Circulation. 2003;107:2684–9.

    PubMed  Google Scholar 

  25. Fearon WF, Shah M, Ng M, et al. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008;51:560–5.

    PubMed  Google Scholar 

  26. Payne AR, Berry C, Doolin O, et al. Microvascular resistance predicts myocardial salvage and infarct characteristics in ST-elevation myocardial infarction. J Am Heart Assoc. 2012;1:e002246.

    PubMed Central  PubMed  Google Scholar 

  27. Araszkiewicz A, Grajek S, Lesiak M, et al. Effect of impaired myocardial reperfusion on left ventricular remodelling in patients with anterior wall myocardial infarction treated with primary coronary intervention. Am J Cardiol. 2006;98:725–8.

    PubMed  Google Scholar 

  28. Brosh D, Asali AR, Mayer A, et al. Effect of no-reflow during primary percutaneous intervention for acute myocardial infarction on six-month mortality. Am J Cardiol. 2007;99:442–5.

    PubMed  Google Scholar 

  29. Kloner RA. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther. 2011;16:244–50.

    PubMed  Google Scholar 

  30. Durante A, Camici PG. Novel insights into an “old” phenomenon: the no reflow. Int J Cardiol. 2015;187:273–80.

    PubMed  Google Scholar 

  31. Barrabes JA, Garcia-Dorado D, Mirabet M, et al. Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia. J Am Coll Cardiol. 2005;45:293–9.

    CAS  PubMed  Google Scholar 

  32. Barrabes JA, Inserte J, Mirabet M, et al. Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. Thromb Haemost. 2010;104:128–35.

    CAS  PubMed  Google Scholar 

  33. Mirabet M, Garcia-Dorado D, Inserte J, et al. Platelets activated by transient coronary occlusion exacerbate ischemia reperfusion injury in rat hearts. Am J Physiol Heart Circ Physiol. 2002;283:H1134–41.

    CAS  PubMed  Google Scholar 

  34. Mirabet M, Garcia-Dorado D, Ruiz-Meana M, Barrabes JA, Soler-Soler J. Thrombin increases cardiomyocyte acute cell death after ischemia and reperfusion. J Mol Cell Cardiol. 2005;39:277–83.

    CAS  PubMed  Google Scholar 

  35. Garcia-Dorado D, Agulló L, Sartorio CL, Ruiz-Meana M. Myocardial protection against reperfusion injury: the cGMP pathway. Thromb Haemost. 2009;101:635–42.

    CAS  PubMed  Google Scholar 

  36. Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS): a 1-year follow-up study. Lancet. 2008;371:1915–20.

    PubMed  Google Scholar 

  37. Sardella G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol. 2009;53:309–15.

    PubMed  Google Scholar 

  38. Liistro F, Grotti S, Angioli P, et al. Impact of thrombus aspiration on myocardial tissue reperfusion and left ventricular functional recovery and remodeling after primary angioplasty. Circ Cardiovasc Interv. 2009;2:376–83.

    PubMed  Google Scholar 

  39. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012;307:1817–26.

    CAS  PubMed  Google Scholar 

  40. Dudek D, Mielecki W, Burzotta F, et al. Thrombus aspiration followed by direct stenting: a novel strategy of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. Results of the Polish-Italian-Hungarian Randomized ThrombEctomy Trial (PIHRATE Trial). Am Heart J. 2010;160:966–72.

    PubMed  Google Scholar 

  41. Frobert O, Lagerqvist B, Olivecrona GK, et al. TASTE trial: thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013;369:1587–97.

    CAS  PubMed  Google Scholar 

  42. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358:557–67.

    CAS  PubMed  Google Scholar 

  43. Tomassini F, Gagnor A, Montali N, et al. Impact of thrombus aspiration during primary percutaneous coronary intervention in cardiogenic shock complicating ST-segment elevation myocardial infarction. Cardiovasc Revasc Med. 2013;14:307–10.

    PubMed  Google Scholar 

  44. Kumbhani DJ, Bavry AA, Desai MY, Bangalore S, Bhatt DL. Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J Am Coll Cardiol. 2013;62:1409–18.

    PubMed  Google Scholar 

  45. De Luca G, Navarese EP, Suryapranata H. A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol. 2013;166:606–12.

    PubMed  Google Scholar 

  46. Jolly SS, Cairns JA, Yusuf S, et al. TOTAL investigators. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. 2015;372:1389–98.

    CAS  PubMed  Google Scholar 

  47. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008;118:49–57.

    CAS  PubMed  Google Scholar 

  48. Bartorelli AL, Trabattoni D, Galli S, Grancini L, Cozzi S, Ravagnani P. Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA. Catheter Cardiovasc Interv. 1999;48:211–3.

    CAS  PubMed  Google Scholar 

  49. Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv. 2004;61:31–4.

    PubMed  Google Scholar 

  50. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895–903.

    CAS  PubMed  Google Scholar 

  51. Stone GW, McLaurin BT, Cox DA, et al. ACUITY Investigators. Bivalirudin for patients withacute coronary syndromes. N Engl J Med. 2006;355:2203–16.

    CAS  PubMed  Google Scholar 

  52. Stone GW, Witzenbichler B, Guagliumi G, et al. HORIZONS-AMI trial investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218–30.

    CAS  PubMed  Google Scholar 

  53. Ishihara M, Sato H, Tateishi H, et al. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J. 1996;132:959–63.

    CAS  PubMed  Google Scholar 

  54. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn. 1996;39:113–8.

    CAS  PubMed  Google Scholar 

  55. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv. 2002;57:444–51.

    PubMed  Google Scholar 

  56. Weyrens FJ, Mooney J, Lesser J, Mooney MR. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol. 1995;75:849–50.

    CAS  PubMed  Google Scholar 

  57. Su Q, Li L, Liu Y. Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Cardiol. 2013;36:E11–6.

    PubMed  Google Scholar 

  58. Skelding KA, Goldstein JA, Mehta L, Pica MC, O’Neill WW. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv. 2002;57:305–9.

    PubMed  Google Scholar 

  59. Ota S, Nishikawa H, Takeuchi M, et al. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J. 2006;70:1099–104.

    CAS  PubMed  Google Scholar 

  60. Kunadian V, Zorkun C, Williams SP, et al. Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction. J Thromb Thrombolysis. 2008;26:234–42.

    CAS  PubMed  Google Scholar 

  61. Amit G, Cafri C, Yaroslavtsev S, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J. 2006;152:887.e9–14.

    Google Scholar 

  62. Kobatake R, Sato T, Fujiwara Y, et al. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessels. 2011;26:379–84.

    PubMed  Google Scholar 

  63. Niccoli G, Rigattieri S, De Vita MR, et al. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine inAcute Myocardial Infarction). JACC Cardiovasc Interv. 2013;6:580–9.

    PubMed  Google Scholar 

  64. Parikh KH, Chag MC, Shah KJ, et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol. 2007;85:476–82.

    CAS  PubMed  Google Scholar 

  65. Pasceri V, Pristipino C, Pelliccia F, et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol. 2005;95:1358–61.

    CAS  PubMed  Google Scholar 

  66. Shinozaki N, Ichinose H, Yahikozawa K, Shimada H, Hoshino K. Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction. Int Heart J. 2007;48:423–33.

    CAS  PubMed  Google Scholar 

  67. Wang HJ, Lo PH, Lin JJ, Lee H, Hung JS. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv. 2004;63:171–6.

    PubMed  Google Scholar 

  68. Youssef AA, Wu CJ, Hang CL, et al. Impact of Percu surge device conjugative with intracoronary administration of nitroprusside on no-reflow phenomenon following primary percutaneous coronary intervention. Circ J. 2006;70:1538–42.

    PubMed  Google Scholar 

  69. Claeys MJ, Bosmans J, De Ceuninck M, et al. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol. 2004;94:9–13.

    CAS  PubMed  Google Scholar 

  70. Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J. 2011;32:867–77.

    CAS  PubMed  Google Scholar 

  71. Fokkema ML, Vlaar PJ, Vogelzang M, et al. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv. 2009;2:323–9.

    CAS  PubMed  Google Scholar 

  72. Grygier M, Araszkiewicz A, Lesiak M, et al. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol. 2011;107:1131–5.

    CAS  PubMed  Google Scholar 

  73. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapyfor acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol. 1999;34:1711–20.

    CAS  PubMed  Google Scholar 

  74. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000;101:2154–9.

    CAS  PubMed  Google Scholar 

  75. Micari A, Belcik TA, Balcells EA, et al. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol. 2005;96:1410–5.

    CAS  PubMed  Google Scholar 

  76. Petronio AS, De Carlo M, Ciabatti N, et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J. 2005;150:1015.

    PubMed  Google Scholar 

  77. Quintana M, Hjemdahl P, Sollevi A, et al. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol. 2003;59:1–9.

    CAS  PubMed  Google Scholar 

  78. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005;45:1775–80.

    CAS  PubMed  Google Scholar 

  79. Stoel MG, Marques KM, de Cock CC, Bronzwaer JG, von Birgelen C, Zijlstra F. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study. Catheter Cardiovasc Interv. 2008;71:283–9.

    PubMed  Google Scholar 

  80. Zhang H, Tian NL, Hu ZY, et al. Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction. Chin Med J (Engl). 2012;125:1713–9.

    CAS  Google Scholar 

  81. Vijayalakshmi K, Whittaker VJ, Kunadian B, et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006;92:1278–84.

    PubMed Central  CAS  PubMed  Google Scholar 

  82. Wallentin L, Becker RC, Budaj A, Investigators PLATO. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.

    CAS  PubMed  Google Scholar 

  83. vanGiezen JJ, Sidaway J, Glaves P, Kirk I, Bjorkman JA. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther. 2012;17:164–72.

    CAS  Google Scholar 

  84. Alexopoulos D, Xanthopoulou I, Tsigkas G et al. Differential effect of Ticagrelor vs Thienopyridine loading on fractional flow reserve: possible implications for clinical practice. circ.ahajournals.org/content/130/Suppl_2/A20443.abstract.

  85. Bonello L, Laine M, Kipson N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63:872–7.

    CAS  PubMed  Google Scholar 

  86. Park SD, Baek YS, Woo SI, et al. Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial. Trials. 2014;15:151.

    PubMed Central  PubMed  Google Scholar 

  87. Garcia-Dorado D, Rodríguez-Sinovas A, Ruiz-Meana M, Inserte J. Protection against myocardial ischemia-reperfusion injury in clinical practice. Rev Esp Cardiol. 2014;67:394–404.

    PubMed  Google Scholar 

  88. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370:1483–93.

    CAS  PubMed  Google Scholar 

  89. Selker HP, Beshansky JR, Sheehan PR, et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA. 2012;307:1925–33.

    PubMed Central  CAS  PubMed  Google Scholar 

  90. Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491–9.

    CAS  PubMed  Google Scholar 

  91. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473–81.

    CAS  PubMed  Google Scholar 

  92. Thuny F, Lairez O, Roubille F, et al. Postconditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59:2175–81.

    PubMed  Google Scholar 

  93. Botker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375:727–34.

    PubMed  Google Scholar 

  94. Syeda B, Schukro C, Heinze G, et al. The salvage potential of coronary sinus interventions: meta-analysis and pathophysiologic consequences. J Thorac Cardiovasc Surg. 2004;127:1703–12.

    PubMed  Google Scholar 

  95. Windecker S, Kolh P, Alfonso F, et al. ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.

    PubMed  Google Scholar 

  96. Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev. 2006;24:116–47.

    CAS  PubMed  Google Scholar 

  97. Layland J, Carrick D, Lee M, Oldroyd K, Berry C. Adenosine: physiology, pharmacology, and clinical applications. JACC Cardiovasc Interv. 2014;7:581–91.

    PubMed  Google Scholar 

  98. Ernens I, Bousquenaud M, Lenoir B, Devaux Y, Wagner DR. Adenosine stimulates angiogenesis by up-regulating production of thrombospondin-1 by macrophages. J Leukoc Biol. 2015;97:9–18.

    CAS  PubMed  Google Scholar 

  99. Inserte J, Garcia-Dorado D. The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism. Br J Pharmacol. 2015;172:1996–2009.

    CAS  PubMed  Google Scholar 

  100. Villarreal F, Zimmermann S, Makhsudova L, et al. Modulation of cardiac remodeling by adenosine: in vitro and in vivo effects. Mol Cell Biochem. 2003;251:17–26.

    CAS  PubMed  Google Scholar 

  101. Kitakaze M, Hori M. Adenosine therapy: a new approach to chronic heart failure. Expert Opin Investig Drugs. 2000;9:2519–35.

    CAS  PubMed  Google Scholar 

  102. Garratt KN, Holmes Jr DR, Molina-Viamonte V, et al. Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am Heart J. 1998;136:196–204.

    CAS  PubMed  Google Scholar 

  103. Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006;27:2400–5.

    CAS  PubMed  Google Scholar 

  104. Quinta ML, Hjemdahl P, Sollevi A, et al. Possible beneficial effects of adenosine as adjuvant therapy to thrombolytic treatment in patients with an acute myocardial infarction and depressed left ventricular function. J Am Coll Cardiol. 2003;41:347A. abstract.

    Google Scholar 

  105. Sakuma T, Motoda C, Tokuyama T, et al. Exogenous adenosine triphosphate disodium administration during primary percutaneous coronary intervention reduces no-reflow and preserves left ventricular function in patients with acute anterior myocardial infarction: a study using myocardial contrast echocardiography. Int J Cardiol. 2010;140:200–9.

    PubMed  Google Scholar 

  106. Wang J, Chen Y, Zhi G, et al. Beneficial effect of adenosine on myocardial perfusion treated with primary percutaneous coronary intervention for acute myocardial infarction. Clin Exp Pharmacol Physiol. 2012;39:247–52.

    CAS  PubMed  Google Scholar 

  107. Kassimis G, Patel N, Dawkins S, et al. First-in-man report of twelve-hour continuous intravenous adenosine infusion in STEMI patients undergoing primary PCI: assessment of feasibility and effects on coronary flow reserve. Eurointervention (Euro-PCR 2014, oral abstract, Euro14A-OP145).

  108. Niccoli G, Spaziani C, Crea F, Investigators REOPEN-AMI. Left ventricular remodeling and 1-year clinical follow-up of the REOPEN-AMI trial. J Am Coll Cardiol. 2014;63:1454–5.

    PubMed  Google Scholar 

  109. Singh M, Shah T, Khosla K, et al. Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Ther Adv Cardiovasc Dis. 2012;6:101–14.

    PubMed  Google Scholar 

  110. Navarese EP, Buffon A, Andreotti F, et al. Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. Atherosclerosis. 2012;222:1–7.

    CAS  PubMed  Google Scholar 

  111. Aung Naing K, Li L, Su Q, Wu T, et al. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev. 2013;6:CD009503.

    PubMed  Google Scholar 

  112. Garcia-Dorado D, García-del-Blanco B, Otaegui I, et al. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. Int J Cardiol. 2014;177:935–41.

    PubMed  Google Scholar 

  113. Garcia-Dorado D, Otaegui I, Rodriguez Palomares JF, et al. Primary results of the PROMISE trial: myocardial protection with intracoronary adenosine given before reperfusion in patients with STEMI. Eur Heart J. 2014;34 Suppl 1:669.

    Google Scholar 

  114. Nazir SA, Khan JN, Mahmoud IZ, et al. The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial. Trials. 2014;15:371.

    PubMed Central  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors declare that they do not have conflict of interest.

Author information

Authors and Affiliations

  1. Department of Cardiology, Asklepeion General Hospital, Athens, Greece

    George Kassimis, Manolis S. Kallistratos & Athanasios J. Manolis

  2. Department of Cardiology, University Hospital of Patras, Rion, Greece

    Periklis Davlouros & Dimitrios Alexopoulos

  3. Oxford Heart Centre, John Radcliffe Hospital, Oxford, UK

    Niket Patel, Gianluigi De Maria, Rajesh K. Kharbanda & Adrian P. Banning

Authors
  1. George Kassimis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Periklis Davlouros
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Niket Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gianluigi De Maria
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manolis S. Kallistratos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rajesh K. Kharbanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Athanasios J. Manolis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dimitrios Alexopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Adrian P. Banning
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George Kassimis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kassimis, G., Davlouros, P., Patel, N. et al. Adenosine as an Adjunct Therapy in ST Elevation Myocardial Infarction Patients: Myth or Truth?. Cardiovasc Drugs Ther 29, 481–493 (2015). https://doi.org/10.1007/s10557-015-6606-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-015-6606-5

Keywords

Search

Navigation